{"entity":{"id":"cartography-biosciences","kind":"company","name":"Cartography Biosciences","aka":[],"tldr":"Cartography Biosciences searches huge maps of single human cells for proteins found only on cancer cells, then builds antibody medicines that steer immune T cells to them; its first drug is in an early trial in bowel cancer.","summary":"Cartography Biosciences, based in South San Francisco and founded by Kevin Parker, Ansu Satpathy and Howard Chang, uses two platforms, ATLAS and SUMMIT, which apply machine learning to single-cell data from healthy and tumour tissue to find targets and target combinations specific to cancer cells. CBI-1214, a T cell engager against an undisclosed novel target, received FDA IND clearance and Fast Track designation in December 2025 and dosed its first patient in a phase 1 trial in microsatellite-stable or MSI-low metastatic colorectal cancer in February 2026 (NCT07321106). CB02 is a preclinical T cell engager, and discovery programmes include logic-gated approaches. It has discovery collaborations with Gilead (announced May 2024; first target option exercised April 2026) and Pfizer (January 2026). Its first registered cancer trial, NCT07321106, was posted on ClinicalTrials.gov in January 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://cartography.bio/"},{"label":"Pipeline","url":"https://cartography.bio/pipeline/"},{"label":"News","url":"https://cartography.bio/news/"},{"label":"ClinicalTrials.gov: phase 1 trial of CBI-1214 (NCT07321106)","url":"https://clinicaltrials.gov/study/NCT07321106"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["immunotherapy","ai-computation"],"technologies":["t-cell-engager","bispecific-antibody","logic-gated-therapeutics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website, pipeline and news page read on 29 October 2026. Founding year not stated on the pages read. The company news page links a October 2025 Business Wire release headlined as a USD 67 million Series B and a May 2026 strategic investment from Samsung Ventures, but those releases refused automated reading, so no funding rows are recorded."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://cartography.bio/","stage":"growth","investors":[],"funding":[]},"route":"/companies/cartography-biosciences/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}]}}